TABLE 2.

Comparison of the in vitro activities of garenoxacin, gemifloxacin, gatifloxacin, and other fluoroquinolones against M. hominis and Ureaplasma clinical isolates and laboratory mutants resistant to fluoroquinolones

Strain	MIC ranges (μg/ml) of antimicrobiala:							Amino acid change in QRDR ofb:
	GAR	GEM	GAT	MXF	LVX	SPX	CIP	GyrA	ParC	ParE
Ureaplasma spp.
Reference strain	0.12	0.25	1	0.25	0.5	0.25	1	None	None	None
Clinical isolatesc
UUe2	0.5	0.5	2	1	2	2	8	None	S80L	None
UUb, -d, -f1, -g1	0.25-0.5	0.25-0.5	2	0.5-1	1	0.5	4-16	D95E	None	None
UUf2, -g2 to g5	0.5-1	1	2	1	4	2-4	16	D95E	S80L	None
UUc	1	0.25	4	1	2	2	8	D95E	E84K	None
UUa	4	2	8	4	16	16	64	Q83R D95E	None	None
M. hominis
Reference strain	≤0.015	0.03	0.06	0.12	0.5	0.06	1	None	None	None
Clinical isolatesd
MHa	0.06	0.25	1	0.5	2	2	16	E87K	E84G	None
MHb1	0.12	0.25	1	1	2	2	16	S83L	S81P	None
MHc1	0.5	0.25	4	2	16	2	32	S83L	None	D426N
MHec	0.5	2	4	4	32	4	16	S83W	S80I	A462V
In vitro mutantse
IS1	0.25	0.12	0.25	0.25	0.5	0.5	2	S83L	None	None
IIS1	1	2	8	8	16	16	32	S83L	E84K	None
IIS3A	2	4	16	16	32	32	64	S83L S84W	None	None
IIIS3A1	4	8	32	16	64	32	128	S83L S84W	E84K	None

^aGAR, garenoxacin; GEM, gemifloxacin; GAT, gatifloxacin; MXF, moxifloxacin; LVX, levofloxacin; SPX, sparfloxacin; CIP, ciprofloxacin.

^bThe quinolone resistance-determining regions (QRDRs) of gyrA, gyrB, parC, and parE were sequenced for all clinical isolates. Escherichia coli numbering is shown.

^cData from reference 3.

^dData from references 3 and 4.

^eData from reference 2.